The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior? - Wikidata - wikimedia - TriplyDB

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

http://www.wikidata.org/entity/Q27030892

about

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial Effects of switching from stavudine to raltegravir on subcutaneous adipose tissue in HIV-infected patients with HIV/HAART-associated lipodystrophy syndrome (HALS). A clinical and molecular study Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial.

P2860

Q26768591-516E683D-BC4A-4099-B8E7-2C4D6D97CE14 Q26799712-AC6816A9-DA8B-41F1-BDC1-BA0A22452F9C Q28540037-7661788C-03E3-452C-A2B2-D71DCBAEB56E Q35106654-B43784C1-925C-4BAF-AC10-DF7E09713EAD Q38381405-7C4A5C8B-6605-46D4-BEFD-5B613BB79095 Q40751471-8E6EE745-7DD2-4E55-A71F-12F832C42F14

P2860

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

http://www.wikidata.org/entity/Q27030892

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@ast

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@en

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@nl

type

label

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@ast

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@en

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@nl

prefLabel

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@ast

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@en

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@nl

P1433

Q27030892-BEB974B2-14FF-4B6A-B466-EA0C24261EC0

P1476

Q27030892-E8E0BE87-1F6D-4345-A7DE-DF687BCF3810

P2093

Q27030892-2D1557B2-75AD-4648-855E-450B0BFBE34B

Q27030892-2D913704-F813-46B9-BAEF-D32DEDEB6D03

Q27030892-7539E6ED-3371-49AF-B567-181888BC848E

P275

Q27030892-5375E471-CC91-4AE5-B143-7495FF491999

P2860

Q27030892-02BF352B-9E0A-41CE-8659-6F0A4923C6B4

Q27030892-1A14BC5F-3F03-4016-91B9-E14990ACABF7

Q27030892-1ED2FD10-A619-41D1-8944-FB8C5E52C836

Q27030892-2653D134-34EE-4533-9AD5-868D0A3E4CE6

Q27030892-366668C2-E335-4FEB-A0DE-F1EFA5A26515

Q27030892-3FD49BB8-49D1-4171-992C-84F4CD84E2C5

Q27030892-559CC6FB-12D7-4EDC-9A77-129DD606017D

Q27030892-5F654FF5-EDEE-4848-A352-FF3E5D1536DF

Q27030892-89B7D987-F82D-4856-A496-949967F6D44A

Q27030892-996850C5-CD94-4AE0-9C6D-BAEE1B1F6135

P304

Q27030892-2066D13B-FDAE-4EAE-9CB5-FD501928B8E0

P31

Q27030892-69D2DA19-FC2C-4670-9E62-1A5ED5F46943

Q27030892-74F163A6-2967-4710-AA1B-713FF3D3BD99

P356

Q27030892-1525E231-2A0F-4989-9B8F-598698D974A3

P407

Q27030892-F9524D0A-5B69-4E6B-87E6-C20BC23DB324

P433

Q27030892-702D5B50-DABA-4C46-A270-1562F5840A5D

P478

Q27030892-824C5DA0-A983-4294-83B4-385B33E34B16

P577

Q27030892-1710C641-76AC-4F0D-B0FB-227A5003AC01

Q27030892-B14CA240-C0E2-49E7-9E94-310251892D03

P5875

Q27030892-5927DC59-6B49-48DF-BD6A-EAB3D3ECBC6A

P698

Q27030892-8A5669CC-3C62-4BA2-B230-3F65FAA9D62A

P921

Q27030892-14320AD3-01C3-4E69-8FEA-2CACB5720BCE

Q27030892-4DB61A96-9C79-42FB-AEAC-F848B9842301

Q27030892-5907AC0C-7D38-4C30-9F29-45EC8FA918E8

Q27030892-8E3170B8-F48D-401F-9AB1-1185B55C3255

P932

Q27030892-A2E1C121-5F9B-4F48-970D-E73454D6CF01

P356

JOURNAL.PMED.1001240

P1433

P1476

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?

@en

P2093

Andrew Carr

http://www.w3.org/2001/XMLSchema#string

Anton Pozniak

http://www.w3.org/2001/XMLSchema#string

Jennifer Hoy

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.

Efficacy and tolerability of initial antiretroviral therapy: a systematic review.

Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.

TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

P304

e1001240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PMED.1001240

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2012-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229427664

http://www.w3.org/2001/XMLSchema#string

P698

22815652

http://www.w3.org/2001/XMLSchema#string

P921

research ethics

antiretroviral drug

biomedical investigative technique

P932

3398965

http://www.w3.org/2001/XMLSchema#string